Compare Novartis AG (NVS) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Block Inc — how do they compare? Novartis AG trades at $152.5 (market cap $295.37B), while Block Inc trades at $77.76 (market cap $47.50B). The key difference: Novartis AG is far larger — about 6.2× Block Inc's market cap, and Novartis AG pays a 3.07% dividend while Block Inc pays none. Which is the better fit depends on your goals.
| NVS | XYZ | |
|---|---|---|
Market Cap | $295.37B | $47.50B |
Sector | Health | Technology |
52-Week High | $168.62 | $84.64 |
52-Week Low | $119.31 | $49.04 |
Enterprise Value | $336.69B | $42.41B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
XYZ trades at $77.78, down 1.52% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $1.02 versus $0.871, driven by 25% gross profit growth in Cash App and Square. The company raised its 2026 profit outlook, reflecting operational momentum amid strategic AI integration and workforce optimization.
The outlook is positive given raised guidance and expanding profitability, but risks include high P/E valuation and net cash flow volatility. Analyst price targets average $99.47, suggesting 28% upside, supported by institutional accumulation and bullish earnings revisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
